NCT02663973 is a clinical trial in Breast Cancer, sponsored by Latin American Cooperative Oncology Group.

Who is sponsoring NCT02663973?

NCT02663973 is sponsored by Latin American Cooperative Oncology Group.

What condition does NCT02663973 study?

NCT02663973 studies Breast Cancer.

Is NCT02663973 still recruiting?

NCT02663973 is currently completed. Last updated 15 June 2021.

Last reviewed 2021-06-15 · How we verify

NCT02663973

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III

Completed Last updated 15 June 2021

What this trial tests

trial in Breast Cancer in 3,000 participants. Completed in 1 April 2021.

Timeline

1 January 2016

Primary endpoint
15 June 2020

1 April 2021

Quick facts

Lead sponsor	Latin American Cooperative Oncology Group
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,000
Start date	1 January 2016
Primary completion	15 June 2020
Estimated completion	1 April 2021
Sites	24 locations across Brazil

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Latin American Cooperative Oncology Group

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The principal goal of this study is to describe the epidemiology of breast cancer in the Brazilian population

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Advanced Stage at Diagnosis and Worse Clinicopathologic Features in Young Women with Breast Cancer in Brazil: A Subanalysis of the AMAZONA III Study (GBECAM 0115).
Franzoi MA, Rosa DD, Zaffaroni F, Werutsky G, et al · · 2019 · cited 25× · PMID 31730380 · DOI 10.1200/jgo.19.00263
Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115).
Maschmann RM, De Jesus RG, Werutsky G, Rebelatto TF, et al · · 2023 · cited 8× · PMID 36586038 · DOI 10.1007/s10549-022-06809-8
The impact of a breast cancer diagnosis on marital outcomes and factors associated with divorce and separation.
Werutsky G, Lopes M, de Jesus RG, Gazola AA, et al · · 2024 · cited 2× · PMID 38994465 · DOI 10.61622/rbgo/2024rbgo60

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Latin American Cooperative Oncology Group trials

Trials by the same sponsor.

NCT07192991 — Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America · not yet recruiting
NCT06822543 — A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastas · Phase 2 · recruiting
NCT06527690 — Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficien · Phase 2 · withdrawn
NCT06279442 — Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort · recruiting
NCT06014580 — Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02663973 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Latin American Cooperative Oncology Group
Last refreshed: 15 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02663973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing